Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Preferred Shares (2021 - 2025)

Historic Preferred Shares for NovaBay Pharmaceuticals (NBY) over the last 5 years, with Q3 2025 value amounting to $3.8 million.

  • NovaBay Pharmaceuticals' Preferred Shares rose 6300000.0% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year increase of 6300000.0%. This contributed to the annual value of $6000.0 for FY2024, which is 9964.18% down from last year.
  • NovaBay Pharmaceuticals' Preferred Shares amounted to $3.8 million in Q3 2025, which was up 6300000.0% from $6000.0 recorded in Q2 2025.
  • In the past 5 years, NovaBay Pharmaceuticals' Preferred Shares ranged from a high of $3.8 million in Q3 2025 and a low of $6000.0 during Q2 2024
  • Moreover, its 5-year median value for Preferred Shares was $644500.0 (2021), whereas its average is $1.1 million.
  • Its Preferred Shares has fluctuated over the past 5 years, first tumbled by 9964.18% in 2024, then soared by 6300000.0% in 2025.
  • NovaBay Pharmaceuticals' Preferred Shares (Quarter) stood at $680000.0 in 2021, then soared by 253.38% to $2.4 million in 2022, then crashed by 30.3% to $1.7 million in 2023, then tumbled by 99.64% to $6000.0 in 2024, then surged by 63000.0% to $3.8 million in 2025.
  • Its Preferred Shares stands at $3.8 million for Q3 2025, versus $6000.0 for Q2 2025 and $6000.0 for Q1 2025.